Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP824 | DOI: 10.1530/endoabs.81.EP824

Hedi Chaker Hospital, Department of Endocrinology, Sfax, Tunisia


Introduction: Growth hormone (GH) treatment in congenital growth hormone deficiency (CGHD) is indicated to improve the prognosis of the statural prognosis. The aim of this study is to identify the predictive factors of a favorable response to GH therapy.

Patients & Methods: This is a retrospective study, conducted over a period of 27 years, including 30 patients with CGHD treated with hormonal therapy.

Results: The CGHD was diagnosed at a mean age of 8.8 ± 3.6 years with a male predominance. Only 2/22 patients reached the target height. The mean stature gain in standard derivations (SD) was 1.8 ± 1.07 SD. Severe growth retardation (86.7%) was positively correlated with stature response (2 vs 0.75 SD; P=0.049). The gain under hormonal treatment did not depend on the GH peak during stimulation tests, nor on the combined (33.3%) or total (73.3%) character of CGHD. The radiological assessment showed a significant association between pituitary stem abnormalities and a better response to GH (2.6 vs. 1.6 SD; P=0.019). The dose and duration of treatment as well as the target size did not influence the evolution under treatment. Only chronological age and delayed bone age at treatment initiation were positively correlated with a good response (P=0.022 and 0.042 respectively).

Conclusion: The results of GH treatment were more satisfactory on final height than on target height. Large-scale prospective studies are needed to validate the factors that seem to be involved in the statural response.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.